



CODEN [USA]: IAJPBB

ISSN: 2349-7750

INDO AMERICAN JOURNAL OF
PHARMACEUTICAL SCIENCES

<http://doi.org/10.5281/zenodo.3870713>

Available online at: <http://www.iajps.com>

Research Article

VITAMIN D-BINDING PROTEIN AS A NEW BIOMARKER IN ANALYSIS OF NEPHROPATHY IN DIABETIC PATIENTS

Dr Shah Rukh Arshad Chaudhary¹, Dr Adnan Karamat², Dr Muneeb Ahmad¹

¹Holy Family Hospital Rawalpindi

²Tehsil Headquarter Hospital Shakargarh, Narowal

Article Received: March 2020

Accepted: April 2020

Published: May 2020

Abstract:

Objectives: The main objective of our study is to find the role of vitamin-D as a biomarker in investigation of nephropathy in diabetic patients. **Methodology of the study:** This cross sectional study was conducted at Holy Family Hospital Rawalpindi during Jan 2019 to October 2019. For the purpose of study 100 patients were selected for further analysis. Those who selected for study were further goes for the analysis of Urine, creatine, Albumin and other series of test. **Results:** Lipid profile of the normal group and diabetic group shows the microalbuminuria and macroalbuminuria of diabetic group. The data presented in the table shows the total protein, serum albumin, serum urea, creatinine, GFR and some inflammatory marker which is vitamin-D. It shows the elevated levels of vitamin-D in diabetic patients. **Conclusion:** It is concluded that vitamin-D binding protein plays an important role and act as serum biomarker for the identification of diabetic nephropathy.

Corresponding author:

Dr Shah Rukh Arshad Chaudhary,
Holy Family Hospital Rawalpindi

QR code



Please cite this article in press Shah Rukh Arshad Chaudhary et al, Vitamin D-Binding Protein As A New Biomarker In Analysis Of Nephropathy In Diabetic Patients., Indo Am. J. P. Sci, 2020; 07(05).

INTRODUCTION:

Diabetes mellitus (DM) belongs to a group of metabolic diseases characterized by hyperglycemia resulting from defects in insulin secretion, insulin action, or both. The chronic hyperglycemia of diabetes is associated with long-term damage, dysfunction, and failure of different organs, especially the eyes, kidneys, nerves, heart, and blood vessels¹. In 2013, according to the International Diabetes Federation, an estimated 381 million people had diabetes. Its prevalence is increasing rapidly, and by 2030 this number is estimated to almost double².

Diabetic nephropathy (DN) is one of the most important long-term complications of diabetes. It is characterized by the development of proteinuria with a subsequent decline in glomerular filtration rate (GFR), which progresses over a long period of time, often over 10-20 years³. Over the past 20 years, the prevalence of DN in the USA has increased in direct proportion to the prevalence of diabetes. Although DN cases vary largely among countries, on average it develops in 30-40% of patients with diabetes⁴.

D-binding protein (DBP), a multifunctional and highly polymorphic plasma protein synthesized primarily in the liver, was identified about half a century ago and characterized as able to bind various forms of vitamin D. DBP (also referred to as Gc-globulin) is a member of the albumin gene family. Vitamin D circulate bound to vitamin D-binding protein (VDBP) (85-90%) and albumin (10-15%),

with less than 1% of circulating hormone in its free form. VDBP prolongs the serum half-life of 25-hydroxyvitamin D and protects against vitamin D deficiency by serving as a vitamin D reservoir⁵.

Objectives:

The main objective of our study is to find the role of vitamin-D as a biomarker in investigation of nephropathy in diabetic patients.

METHODOLOGY OF THE STUDY:

This cross sectional study was conducted at Holy Family Hospital Rawalpindi during Jan 2019 to October 2019. For the purpose of study 100 patients were selected for further analysis. Those who selected for study were further goes for the analysis of Urine, creatine, Albumin and other series of test. 5cc blood sample was taken from vein. Blood was further processed for the estimation of albumin and protein. Commercially available enzymatic kits of Randox were used. Blood was centrifuged at 4000 rpm for 10 minutes and serum was separated. Blood samples will be collected into EDTA tubes from fasting proteins. The blood will be centrifuged and indomethacin and butylated hydroxytoluene will be added into the plasma samples before they will be stored at -80°C until analysis. The collected data were analyzed using SPSS software (version 17).

RESULTS:

Table 01 shows the basic characteristics of the study group. These include blood pressure, HEI, BMI, smoking habits and some other basic things.

Table 01: Demographic characteristics of the diabetic group

Variables	Co-efficient	SE
Blood pressure	0.048	0.35
Healthy eating index (HEI)	-0.059	0.05
Smoker	0.060	0.80
Food security	0.106	0.12
Drinker	-0.343	0.08
Belong to city area	0.057	0.01
Belong to rural area	0.59	0.70
BMI	0.5460.24	

Table 02 shows the lipid profile of the normal group and diabetic group. It also shows the microalbuminuria and macroalbuminuria of diabetic group. The data presented in the table shows the total protein, serum albumin, serum urea, creatinine, GFR and some inflammatory marker which is vitamin-D. It shows the elevated levels of vitamin-D in diabetic patients.

Table 02: Parameters of the study group

Variables	Control group	Diabetic groups			values
		Normal albuminuria	Microalbuminuria	Macroalbuminuria	
		N=50	N=50	N=50	
Lipid profile					
Total cholesterol (mmol/l)	4.8 ± 1.5	4.8 ± 0.7	4.6 ± 0.9	5.1 ± 1.4	0.289
HDL-c (mmol/l)	1.2 ± 0.4	1.2 ± 0.3	1.1 ± 0.4	0.9 ± 1.0	0.196
LDL-c (mmol/l)	6.9 ± 24.5	3.3 ± 0.6	3.4 ± 1.1	1.12 ± 0.4	0.417
Diabetic assessment					
HbA1c (%)	4.7 ± 0.4	7.2 ± 0.7 ^a	7.5 ± 1.4 ^a	9.4 ± 0.8 ^{a,b,c}	<0.001
Fasting insulin (mIU/l)	9.6 ± 5.0	25.3 ± 10.4 ^a	32.3 ± 14.4 ^{a,b}	37.8 ± 16.8 ^{a,b}	<0.001
Total protein (gm/l)	74.2 ± 10.4	73.9 ± 3.2	70.7 ± 4.2	71.9 ± 5.5	0.052
Serum albumin (gm/l)	47.7 ± 7.7	35.0 ± 3.3 ^a	34.1 ± 2.4 ^a	34.4 ± 2.5 ^a	<0.001
Renal function tests					
Serum urea (mmol/l)	3.5 ± 1.1	4.6 ± 1.0 ^a	4.5 ± 0.9 ^a	4.5 ± 1.4 ^a	<0.001
Serum creatinine (µmol/l)	57.7 ± 12.5	56.2 ± 16.0	59.1 ± 9.8	69.2 ± 16.6 ^{a,b,c}	<0.001
Albumin/creatinine ratio (µg/mg)	16.7 ± 8.7	10.5 ± 7.8	77.5 ± 65.5	803.5 ± 355 ^{a,b,c}	<0.001
eGFR (ml/min/1.73 m ²)	102.4 ± 17.6	111.2 ± 36.6	107.9 ± 17.2	113.3 ± 22.9	0.232
Inflammatory markers					
hs-CRP (mg/l)	0.12 ± 0.08	0.17 ± 0.05 ^a	0.17 ± 0.04 ^a	0.15 ± 0.02 ^{a,b,c}	<0.001
VDBP analyses					
sVDBP (µg/ml)	210.3 ± 33.8	202.4 ± 43.9	248.4 ± 36.5 ^{a,b}	299.2 ± 50.6 ^{a,b,c}	<0.001
uVDBP/uCr (ng/mg)	127.7 ± 21.9	193.1 ± 141.0	820.4 ± 402.8 ^{a,b}	1458.1 ± 210 ^{a,b,c}	<0.001

DISCUSSION:

The identification of novel biomarkers of the early stages of DN is mandatory in an attempt to reduce the burden of chronic kidney diseases in diabetic patients⁶. To evaluate whether uVDBP levels could be a novel noninvasive biomarker for DN in a sample of Saudi population, the current study results demonstrated that the uVDBP levels were highly elevated in Saudi patients with DN and were correlated significantly with the severity (degree of albuminuria) of DN. Interestingly, the human VDBP gene is a member of a multigene cluster residing on chromosome 4 and coding for related albumin proteins which have structural and functional similarities⁷. In the normal kidney, VDBP as a 25-(OH) vitamin D3/VDBP complex is reabsorbed by megalin-mediated endocytosis and catabolized by epithelial cells of the proximal tubules contributing to the reduction of its urinary excretion levels. Clinically, it has been found that excessive excretion of uVDBP could indicate tubular dysfunction which was considered as one of the early hallmarks of DN.

The reasons underlying the enhanced excretion of UVDBP in patients with DN may be associated with renal tubular damage in DN patients. It has been increasingly documented that renal tubular injury plays an integral role in the pathogenesis of diabetic kidney disease. In addition, tubulointerstitial lesions were found to be the early and independent features of diabetic kidney disease⁷⁻⁹. They also indicated that damaged tubular epithelial cells in areas of tubulointerstitial fibrosis may no longer be able to handle VDBP, resulting in gross VDBP loss into the urine, and that it can be modulated by anti-proteinuric treatment in patients. Although the combination of the renin-angiotensin-aldosterone system blockade and dietary sodium restriction, an intervention considered optimal for reno protection, considerably reduced VDBP excretion, they demonstrated that UVDBP excretion is increased early after renal injury and is associated with tubulointerstitial inflammation and fibrosis independently of albuminuria¹⁰.

CONCLUSION:

It is concluded that vitamin-D binding protein plays an important role and act as serum biomarker for the identification of diabetic nephropathy.

REFERENCES:

1. Meguro S, Shigihara T, Kabeya Y, Tomita M, Atsumi Y. Increased risk of renal deterioration associated with low e-GFR in type 2 diabetes mellitus only in albuminuric subjects. *Intern Med* 2009; **48** :657-663.
2. Ninomiya T, Perkovic V, de Galan BE, Zoungas S, Pillai A, Jardine M, et al., ADVANCE Collaborative Group Albuminuria

and kidney function independently predict cardiovascular and renal outcomes in diabetes. *J Am Soc Nephrol* 2009; **2**:1813-1821

3. Mirkoviac K, Doorenbos CR, Dam WA, Lambers Heerspink HJ, Slagman MC, et al. Urinary vitamin D binding protein: a potential novel marker of renal interstitial inflammation and fibrosis. *PLoS One* 2013; **8**:e55887. doi: 10.1371/journal.pone.0055887. Epub 2013 Feb 11
4. Uchida M, Teranishi H, Aoshima K, Katoh T, Kasuya M, Inadera, H. Elevated urinary levels of vitamin D-binding protein in the inhabitants of a cadmium polluted area, Jinzu River basin, Japan. *Tohoku J Exp Med*. 2007; **211** :269-274
5. Lau GJ, Godin N, Maachi H, Lo CS, Wu SJ, Zhu JX, et al. Bcl-2-modifying factor induces renal proximal tubular cell apoptosis in diabetic mice. *Diabetes* 2012; **61** :474-484
6. Li F, Chen DN, He CW, Zhou Y, Olkkonen VM, He N, et al. Identification of urinary Gc-globulin as a novel biomarker for bladder cancer by two-dimensional fluorescent differential gel electrophoresis (2D-DIGE). *J Proteomics* 2012; **77** :225-236
7. Chun RF, Peercy BE, Adams JS, Hewison M. Vitamin D binding protein and monocyte response to 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D: analysis by mathematical modeling. *PLoS One* 2012; **7** :e30773.
8. De Boer IH, Rue TC, Hall YN, Heagerty PJ, Weiss NS, Himmelfarb J. Temporal trends in the prevalence of diabetic kidney disease in the United States. *JAMA* 2011; **305** :2532-2539.
9. B. M. Svoren, L. K. Volkening, J. R. Wood, and L. M. Laffel, "Significant vitamin D deficiency in youth with type 1 diabetes mellitus," *The Journal of Pediatrics*, vol. 154, no. 1, pp. 132-134, 2009
10. W. T. Friedewald, R. I. Levy, and D. S. Fredrickson, "Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge," *Clinical Chemistry*, vol. 18, no. 6, pp. 499-502, 1972.